Composite PI3K-AKT-GSK3B-CTNNB1 and RAS-RAF-MEK-ERK signaling pathways (PI3K/AKT and MAPK signaling cascades)

This composite target represents the integration of two primary intracellular signaling axes: the Phosphatidylinositol 3-kinase (PI3K)/AKT/Glycogen synthase kinase 3 beta (GSK3B)/Catenin beta 1 (CTNNB1) pathway and the RAS/RAF/Mitogen-activated protein kinase kinase (MAP2K1)/Mitogen-activated protein kinase (MAPK) cascade. These pathways are central regulators of cell growth, metabolism, and survival in response to extracellular growth factors (PubMed: 30107119). The PI3K/AKT arm primarily modulates glucose uptake and protein synthesis, while the MAPK arm drives cell cycle progression and differentiation (PubMed: 29973711). GSK3B and CTNNB1 serve as critical nodes linking these pathways to Wnt signaling, influencing cell fate and structural integrity (PubMed: 22508264). In many cancers, these pathways are constitutively activated through mutations in genes like PIK3CA, KRAS, or BRAF, leading to uncontrolled proliferation and resistance to apoptosis. Because of extensive crosstalk and compensatory feedback loops between these two networks, simultaneous or sequential inhibition of components in both pathways is a major focus of modern precision oncology to prevent the emergence of drug resistance (PubMed: 25501587).

Other names

PI3K/AKT/mTOR pathwayMAPK/ERK pathwayRAS-RAF-MEK-ERK cascadeWnt/beta-catenin signaling axisGrowth factor signaling network

Inhibition of catalytic kinase activity (ATP-competitive or allosteric), inhibition of GTPase membrane localization, and modulation of protein-protein interactions to block downstream signaling flux.